ReForm Biologics and Astellas Pharma have formed a collaboration to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform transforms the formulation of biotherapeutics in order to enable alternative dosing, improve manufacturing efficiency and extend product life-cycles.   Under the terms of the agreement, Astellas will provide funding for the collaboration and the work will be performed at ReForm Biologics’ facilities in Woburn, MA.   “We a...